Pay in 4 interest-free payments of $7.14 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
Continued optimization of biodegradable materials and scalable manufacturing processes will be essential for advancing GSH-responsive systems toward clinical application
Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released phase 2 trial results demonstrating 25% weight loss in half of people with #obesity
Lower pricing could allow clinicians to initiate GLP-1 treatment earlier for patients who previously could not afford these medications
But raw percentages can be misleading without understanding the trial designs, patient populations, and timelines involved
At week 52, 80 mg resmetirom, 100 mg, and placebo led to -42.1%, -51.4% and -10.4% change from baseline in MRI-PDFF, while Fibroscan CAP changed by -39.6%, -41.3%, and -14.5% respectively
